Published in Transfus Med Rev on January 01, 1989
Synthesis and use of synthetic oligonucleotides. Annu Rev Biochem (1984) 4.53
Ribozymes as potential anti-HIV-1 therapeutic agents. Science (1990) 4.49
Ribozyme-mediated inhibition of HIV 1 suggests nucleolar trafficking of HIV-1 RNA. Proc Natl Acad Sci U S A (2000) 1.88
The expression cassette determines the functional activity of ribozymes in mammalian cells by controlling their intracellular localization. RNA (1997) 1.84
Direct detection of HIV-1 RNA from AIDS and ARC patient samples. DNA (1988) 1.79
Facilitation of hammerhead ribozyme catalysis by the nucleocapsid protein of HIV-1 and the heterogeneous nuclear ribonucleoprotein A1. EMBO J (1994) 1.77
Inhibition of human immunodeficiency virus by using an oligonucleoside methylphosphonate targeted to the tat-3 gene. J Virol (1988) 1.73
Expression of small, therapeutic RNAs in human cell nuclei. Gene Ther (1997) 1.71
Unexpected point mutations activate cryptic 3' splice sites by perturbing a natural secondary structure within a yeast intron. Genes Dev (1991) 1.70
Structure and organization of the two tRNATyr gene clusters on the E. coli chromosome. Cell (1979) 1.68
An alternate method for synthesis of double-stranded DNA segments. J Biol Chem (1982) 1.63
The first ATPase domain of the yeast 246-kDa protein is required for in vivo unwinding of the U4/U6 duplex. RNA (1999) 1.62
Partial purification and some properties of delta1-pyrroline-5-carboxylate reductase from Escherichia coli. J Bacteriol (1977) 1.49
Proline excretion and indirect suppression in Escherichia coli and Salmonella typhimurium. J Bacteriol (1974) 1.41
Differential transcription of Pgk genes during spermatogenesis in the mouse. Dev Biol (1992) 1.41
Detection of drug resistance in human tumors by in vitro enzymatic amplification. Cancer Res (1988) 1.40
Differential recovery of auxotrophs after penicillin enrichment in Escherichia coli. J Bacteriol (1971) 1.39
Ribozyme-mediated cleavage of c-fos mRNA reduces gene expression of DNA synthesis enzymes and metallothionein. Proc Natl Acad Sci U S A (1991) 1.37
Progress and prospects: RNA-based therapies for treatment of HIV infection. Gene Ther (2007) 1.34
Biological expression of an Escherichia coli consensus sequence promoter and some mutant derivatives. Proc Natl Acad Sci U S A (1983) 1.33
Engineering and optimization of the miR-106b cluster for ectopic expression of multiplexed anti-HIV RNAs. Gene Ther (2008) 1.32
RNA accessibility prediction: a theoretical approach is consistent with experimental studies in cell extracts. Nucleic Acids Res (2000) 1.27
Foamy combinatorial anti-HIV vectors with MGMTP140K potently inhibit HIV-1 and SHIV replication and mediate selection in vivo. Gene Ther (2009) 1.27
A test for intron function in the yeast actin gene. Nature (1985) 1.24
Identification and characterization of yeast mutants that overcome an experimentally introduced block to splicing at the 3' splice site. RNA (1996) 1.24
Chimeric DNA-RNA hammerhead ribozymes have enhanced in vitro catalytic efficiency and increased stability in vivo. Nucleic Acids Res (1992) 1.24
Yeast pre-messenger RNA splicing efficiency depends on critical spacing requirements between the branch point and 3' splice site. EMBO J (1986) 1.22
Inhibition of HIV-1 in human T-lymphocytes by retrovirally transduced anti-tat and rev hammerhead ribozymes. Gene (1994) 1.13
Lentiviral-mediated delivery of siRNAs for antiviral therapy. Gene Ther (2006) 1.11
Structural organization of Escherichia coli tRNAtyr gene clusters in four different transducing bacteriophages. J Mol Biol (1979) 1.10
Allogeneic bone marrow transplantation, zidovudine, and human immunodeficiency virus type 1 (HIV-1) infection. Studies in a patient with non-Hodgkin lymphoma. Ann Intern Med (1989) 1.08
Oligonucleotide probes for the detection of TEM-1 and TEM-2 beta-lactamase genes and their transposons. Can J Microbiol (1987) 1.06
Inhibition of bcr-abl oncogene expression by novel deoxyribozymes (DNAzymes). Hum Gene Ther (1999) 1.04
Isolation and functional analysis of a Kluyveromyces lactis RAP1 homologue. Gene (1994) 1.02
Detection of antisense and ribozyme accessible sites on native mRNAs: application to NCOA3 mRNA. Mol Ther (2001) 1.00
Kluyveromyces lactis maintains Saccharomyces cerevisiae intron-encoded splicing signals. Mol Cell Biol (1989) 0.98
Isolation of a mouse pseudo tRNA gene encoding CCA--a possible example of reverse flow of genetic information. Nature (1982) 0.97
Rapid determination and quantitation of the accessibility to native RNAs by antisense oligodeoxynucleotides in murine cell extracts. Nucleic Acids Res (1998) 0.97
Downregulation of the CCR5 beta-chemokine receptor and inhibition of HIV-1 infection by stable VA1-ribozyme chimeric transcripts. Antisense Nucleic Acid Drug Dev (2000) 0.97
Ribozyme-mediated inhibition of bcr-abl gene expression in a Philadelphia chromosome-positive cell line. Blood (1993) 0.95
Current progress in the development of RNAi-based therapeutics for HIV-1. Gene Ther (2011) 0.93
Intracellular applications of ribozymes. Methods Enzymol (2001) 0.92
Proline excretion in Escherichia coli: a comparison of an argD+ strain and a proline-excreting argD- derivative. Biochem Genet (1977) 0.91
Effect of enrichment procedure upon auxotroph recovery in Escherichia coli K-12. Antimicrob Agents Chemother (1975) 0.91
Biological and functional aspects of catalytic RNAs. Crit Rev Eukaryot Gene Expr (1992) 0.91
Ribozyme-mediated cleavage of an HIV-1 gag RNA: the effects of nontargeted sequences and secondary structure on ribozyme cleavage activity. Antisense Res Dev (1991) 0.91
Ribozyme-mediated inhibition of rat leukocyte-type 12-lipoxygenase prevents intimal hyperplasia in balloon-injured rat carotid arteries. Circulation (2001) 0.90
Use of polymerase chain reaction to detect the expression of the Mr 70,000 heat shock genes in control or heat shock leukemic cells as correlated to their heat response. Cancer Res (1990) 0.89
Adenoviral delivery of a leukocyte-type 12 lipoxygenase ribozyme inhibits effects of glucose and platelet-derived growth factor in vascular endothelial and smooth muscle cells. Circ Res (2001) 0.87
Detection by enzymatic amplification of bcr-abl mRNA in peripheral blood and bone marrow cells of patients with chronic myelogenous leukemia. Blood (1989) 0.86
Ribozyme-mediated RNA degradation in nuclei suspension. Nucleic Acids Res (1995) 0.86
RNAi therapeutics: SNALPing siRNAs in vivo. Gene Ther (2006) 0.86
Status of ribozyme and antisense-based developmental approaches for anti-HIV-1 therapy. Ann N Y Acad Sci (1992) 0.85
Ribozymes: use as anti-HIV therapeutic molecules. Antisense Res Dev (1993) 0.85
Innate immunity confounds the clinical efficacy of small interfering RNAs (siRNAs). Gene Ther (2009) 0.85
Protecting from R5-tropic HIV: individual and combined effectiveness of a hammerhead ribozyme and a single-chain Fv antibody that targets CCR5. Gene Ther (2004) 0.85
Arginine side-chain dynamics in the HIV-1 rev-RRE complex. J Mol Biol (2000) 0.84
Enhancement of ribozyme function by RNA binding proteins. Methods Mol Biol (1997) 0.84
Monitoring retroviral RNA dimerization in vivo via hammerhead ribozyme cleavage. J Virol (1998) 0.84
Substitution of non-catalytic stem and loop regions of hammerhead ribozyme with DNA counterparts only increases KM without sacrificing the catalytic step (kcat): a way to improve substrate-specificity. Nucleic Acids Symp Ser (1992) 0.84
Oligonucleotide scanning of native mRNAs in extracts predicts intracellular ribozyme efficiency: ribozyme-mediated reduction of the murine DNA methyltransferase. Mol Ther (2000) 0.84
An inexpensive membrane filtration manifold. Anal Biochem (1975) 0.83
Stem cells, ribozymes and HIV. Gene Ther (2009) 0.83
Intracellular ribozyme applications. Biochem Soc Trans (2002) 0.83
Evidence that a leukocyte type of 12-lipoxygenase is expressed and regulated by angiotensin II in human adrenal glomerulosa cells. Endocrinology (1994) 0.82
Correlation of activity with stability of chemically modified ribozymes in nuclei suspension. Antisense Nucleic Acid Drug Dev (1996) 0.82
Delivery of an anti-HIV-1 ribozyme into HIV-infected cells via cationic liposomes. Biochim Biophys Acta (1998) 0.81
In vivo, high-resolution analysis of yeast and mammalian RNA-protein interactions, RNA structure, RNA splicing and ribozyme cleavage by use of terminal transferase-dependent PCR. Nucleic Acids Res (2000) 0.81
Small sequence insertions within the branch point region dictate alternative sites of lariat formation in a yeast intron. Nucleic Acids Res (1992) 0.80
A chimeric tRNA(Lys3)-ribozyme inhibits HIV replication following virion assembly. Nucleic Acids Symp Ser (1995) 0.80
Antisense catalytic RNAs as therapeutic agents. Adv Pharmacol (1994) 0.80
Structural similarities between hammerhead ribozymes and the spliceosomal RNAs could be responsible for lack of ribozyme cleavage in yeast. Antisense Nucleic Acid Drug Dev (1998) 0.79
Expression of hammerhead ribozymes by retroviral vectors to inhibit HIV-1 replication: comparison of RNA levels and viral inhibition. Antisense Nucleic Acid Drug Dev (1996) 0.79
Procedure for isolating mutants defective in metabolite transport or utilization. J Bacteriol (1975) 0.79
PCR-based quantitation of low levels of HIV-1 DNA by using an external standard. Genet Anal Tech Appl (1992) 0.78
Functional expression of a yeast ochre suppressor tRNA gene in Escherichia coli. Gene (1982) 0.78
Virion encapsidation of tRNA(3Lys)-ribozyme chimeric RNAs inhibits HIV infection. Antisense Nucleic Acid Drug Dev (1998) 0.78
Unusual interactions between cleavage products of a cis-cleaving hammerhead ribozyme. Antisense Nucleic Acid Drug Dev (1998) 0.77
Anti-HIV therapy with antisense oligonucleotides and ribozymes: realistic approaches or expensive myths? J Antimicrob Chemother (1996) 0.77
Intracellular expression and function of antisense catalytic RNAs. Methods Enzymol (2000) 0.77
Topical antiviral siRNA: a practical siRNA microbicide? Gene Ther (2006) 0.77
Altered response to growth rate changes in Kluyveromyces lactis versus Saccharomyces cerevisiae as demonstrated by heterologous expression of ribosomal protein 59 (CRY1) Nucleic Acids Res (1991) 0.76
Ribozymes expressed within the loop of a natural antisense RNA form functional transcription terminators. Gene (1995) 0.76
Expression of the human immunodeficiency virus type 1 primer binding sequence inhibits HIV-1 replication. Hum Gene Ther (1998) 0.76
Functional colocalization of ribozymes and target mRNAs in Drosophila oocytes. FASEB J (2001) 0.76
Hammerhead ribozyme-mediated cleavage of the human insulin-like growth factor-II ribonucleic acid in vitro and in prostate cancer cells. Endocrinology (1999) 0.76
Delivery of novel macromolecular drugs against HIV-1. Expert Opin Biol Ther (2001) 0.75
Cooperative interaction of branch signals in the actin intron of Saccharomyces cerevisiae. Nucleic Acids Res (1998) 0.75
Polymerase chain reaction detection of human immunodeficiency virus DNA in human periradicular lesions. J Endod (1994) 0.75
Enhanced inhibition of HIV-1 replication in macrophages by antisense oligonucleotides, ribozymes and acyclic nucleoside phosphonate analogs delivered in pH-sensitive liposomes. Nucleosides Nucleotides Nucleic Acids (2001) 0.75
Can alcoholism be treated in a mental hospital? Psychiatry Dig (1966) 0.75
Medical offices subsidized by Cabrini Hospital, Chicago; hospital survival plan. Hosp Prog (1974) 0.75
Glass beads as a model matrix for solvent-deposition of drugs [proceedings]. J Pharm Pharmacol (1979) 0.75
Enzymatic synthesis of oligoribonucleotides of defined sequence. DNA (1987) 0.75
The relationship of MMPI subtype membership to demographic variables and treatment outcome among substance misusers. J Stud Alcohol (1983) 0.75
Selecting a CPA firm. Hosp Prog (1978) 0.75
Persistence of bcr-able gene expression following bone marrow transplantation for chronic myelogenous leukemia in chronic phase. Transplantation (1991) 0.75
Structural components of an alcoholism treatment program. Evaluations by patients and staff. Q J Stud Alcohol (1974) 0.75
Antiviral applications of RNAi. Handb Exp Pharmacol (2006) 0.75